WO2023144727 - ANTI-GLYCOPROTEIN D ANTIBODIES, METHODS OF PREPARATION, AND USES THEREOF
National phase entry:
Publication Number
WO/2023/144727
Publication Date
03.08.2023
International Application No.
PCT/IB2023/050640
International Filing Date
25.01.2023
Title **
[English]
ANTI-GLYCOPROTEIN D ANTIBODIES, METHODS OF PREPARATION, AND USES THEREOF
[French]
ANTICORPS ANTI-GLYCOPROTÉINE D, PROCÉDÉS DE PRÉPARATION ET UTILISATIONS DE CEUX-CI
Applicants **
VIROGIN BIOTECH CANADA LTD.
LIU, Xiaohu
MURAD, Yanal M
Inventors
LIU, Xiaohu
MURAD, Yanal M
Priority Data
63/303,067
26.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2729 | |
| EPO | Filing, Examination, Granting | 17720 | |
| Japan | Filing, Examination, Granting | 2692 | |
| South Korea | Filing, Examination, Granting | 3250 | |
| USA | Filing, Examination, Granting | 10940 |
Total:
37,331
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides antibodies that bind to a gD protein. The present disclosure also discloses a composition comprising an anti-gD protein antibody, a pharmaceutical composition comprising an anti-gD protein antibody and a pharmaceutically acceptable carrier. Also disclosed are a polynucleotide sequence encoding an anti-gD protein, a vector comprising such a polynucleotide, and a cell capable of expressing an anti-gD protein. The present disclosure also provides a method for producing an anti-gD protein antibody, a method for treating HSV-1 and/or HSV-2 infection, and a method for detecting HSV-1 and/or HSV-2.[French]
La présente invention concerne des anticorps qui se lient à une protéine gD. La présente invention concerne également une composition comprenant un anticorps anti-protéine gD, une composition pharmaceutique comprenant un anticorps anti-protéine gD et un véhicule pharmaceutiquement acceptable. L'invention concerne également une séquence polynucléotidique codant pour un anti-protéine gD, un vecteur comprenant un tel polynucléotide, et une cellule capable d'exprimer un anti-protéine gD. La présente invention concerne également un procédé de production d'un anticorps anti-protéine gD, une méthode de traitement d'une infection par le HSV-1 et/ou le HSV-2, et une méthode de détection du HSV-1 et/ou du HSV-2.